Boehringer Ingelheim announced Cyltezo (adalimumab-adbm), a FDA-approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the U.S.
Boehringer Ingelheim announced that the FDA has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira (adalimumab)
Boehringer announced the FDA has approved the supplemental Biologics License Application (sBLA) for Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases and this latest approval designates it as Interchangeable across all of these indications.
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Boehringer announced results from a phase III study, confirming that Cyltezo (adalimumab biosimilar) is equivalent to Humira, with no clinically...
Boehringer Ingelheim announced that the FDA approved Cyltezo (adalimumab biosimilar), in a pre-filled syringe for the treatment of multiple chronic...
In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data.